03 March 2023 : Original article
Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience
Maha M. Islami
1CDE*, Mansoor Ahmed Khan 23ABCDEF, Mohammed A. Aseeri 23A, Majed A. Alshamrani 23E, Abdelmajid Alnatsheh 23ACDE, Sameer Alamoudi 34ADE, Ahmed A. Alzahrani 5E
DOI: 10.12659/AOT.938585
Ann Transplant 2023; 28:e938585
Table 2 Mobilization results.
| Parameters | Zarzio® | Neupogen® | P value | |
|---|---|---|---|---|
| Autologous | Time to successful harvest | |||
| Filgrastim + chemotherapy | 14 | 15 | 0.477 | |
| Filgrastim | 5 | 5 | 0.657 | |
| CD34+ ×10/kg | ||||
| Filgrastim + chemotherapy | 5 | 5.5 | 0.641 | |
| Filgrastim | 3.76 | 4.44 | 0.214 | |
| Allogeneic (healthy donors) | Time to successful harvest | 4 | 4 | 0.576 |
| CD34+ ×10/kg | 6.445 | 6 | 0.347 | |